Image Credit: PharmaVoice
Eli Lilly and Company inaugurates the new Lilly Gateway Labs (LGL) site in San Diego, California. The company is extending its reach of shared innovation hubs engineered to help early-stage biotechnology companies by availing the opportunities and lab space to partner with Lilly scientists. The new facility is established and operated in collaboration with Alexandria Real Estate Equities, Inc., and is situated on the one Alexandria Square megacampus in Torrey Pines. The LGL San Diego consists of 82,514 square feet of brilliantly engineered laboratory and office area to accommodate around 15 life sciences companies with over 250 employees of LGL-related companies. This new site launch will strengthen Lilly’s network and fuel expansion growth.
The Lilly Gateway Labs enables startups access to wet lab facilities with trimmed scientific involvement and smart guidance to help map the critical aspects of drug development and discovery. The model is developed to leverage the progress towards major profits by merging infrastructure with excellent expertise. The LGL San Diego is Lilly’s fourth newest US gateway lab site that connects two areas in South San Francisco and another in Boston. The model is extending worldwide with its newly inaugurated LGL site in Beijing. With its first-ever 2019 gateway labs site opening, the LGL-related companies have obtained over $2 billion in capital, fueling the development of over 50 platforms and therapeutics currently in progress.
The gateway labs-based companies show a unique array of therapeutic ideas and disease spaces, lined up with and outside of Lilly’s deep-focused areas. The LGL San Diego has attracted the attention of numerous early-stage biotech companies, accelerating the next-generation modalities to work on a few of the body’s critical systems and hard-to-treat diseases.
The MD, PhD, Chief Scientific Officer and president at Lilly Research Laboratories and Lilly Immunology, Daniel Skovronsky, said, “At Lilly, we’re dedicated to satisfying the biotech ecosystem on its own terms, helping companies at all stages and emerging alongside them. The future of medicine relies on the merged power of large pharma, biotech, and academia to resolve a few of the stressful diseases that patients face. Our extensional appearance here allows us to coordinate with San Diego’s immersive startup community, leading research institutions, and scientists. With the help of communicable spaces such as Lilly Gateway Labs, we’re allowing bold science to flourish.”
Holding MSC in Biotechnology, Sushma Singh is a seasoned editor at Towards Healthcare, with over three years of experience delivering insightful and accurate news in the healthcare, biotechnology, and pharmaceutical domains.
